News Overview

Natco believes the warning letter won't impact supplies or existing revenues from the facility but may cause delays in pending product approvals.

Gland Pharma's stock fell 6% after the trade and was trading at ₹1,751 on the National Stock Exchange.

The developer said in a regulatory statement that the result helped them record their best-ever quarterly and yearly sales.

Quarter on quarter (QoQ), advances grew by 4.47% in Q4 FY24 from ₹1.79 Lakh Crore as of December 31, 2023.

The addition of this new assembly line to the Manesar unit's existing plant-A has greatly increased Maruti's overall production.

Metal index surged by 2.07%, followed by Realty index at 1.09%. Bank, Financial Services, IT, Healthcare, and Consumer Durables indices also registered gains.

Moving annual turnover (MAT) from April 2023 to March 2024 increased by 6.5%, totaling Rs 1.98 trillion, while domestic market volumes dipped by 1%.

Collaborating closely with Orbicular Pharmaceutical Technologies Private Limited, Gland Pharma is actively engaged in the co-development of several complex injectables, including Eribulin Mesylate Injection.

The NFO is available for subscription from April 08 to April 22. The schemes will reopen for continuous sale and repurchase within five Business Days from the date of allotment.

Full-year sales witnessed a 20% YoY increase, with wholesale volumes reaching 401,303 units (up 25%) and retail sales totaling 431,733 units (up 22%).